Back

Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Myocardial Disease ePosters Infiltrative Myocardial Disease ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Thibaud Damy

University Hospital Henri Mondor, Creteil (France)

106 More presentations in this session

Presentation thumbnail
Comparative genetic, clinical features, and 5-years outcomes for dilated vs noncompaction cardiomyopathy
Doctor T. Vaikhanskaya (Minsk, BY)
Abstract Slides
Presentation thumbnail
Survival analysis in arrhythmogenic/dilated cardiomyopathy caused by pathogenic DSP truncating variants
Doctor A. Lamounier Junior (A Coruna, ES)
Abstract Slides
Presentation thumbnail
Clinical profiles and incident heart failure in cardiomyopathies: a population-based linked electronic health record cohort study
Doctor J. Brownrigg (Surrey, GB)
Abstract Slides
Presentation thumbnail
Clinical features, risk factors, and prognosis of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP like regimen
Assistant Professor T. Nakayama (Nagoya, JP)
Abstract Slides
Presentation thumbnail
Two common echocardiographic variables to diagnose cardiac amyloidosis: the AMYLoidosis Index (AMYLI) score
Doctor G. Vergaro (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Myocardial Disease ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy
21 May 2022
thumbnail
Congress Presentation
The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and prognostic meta-analysis
20 June 2025
thumbnail
Webinar
New drugs in the treatment of amyloidosis
16 July 2025
thumbnail
Congress Presentation
Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
11 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources